Compare Agilent Technologies Inc (A) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Amgen, Inc. — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Amgen, Inc. trades at $367.99 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 5.4× Agilent Technologies Inc's market cap, and Amgen, Inc. pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| A | AMGN | |
|---|---|---|
Market Cap | $37.04B | $198.67B |
Sector | Health | Health |
52-Week High | $157.20 | $388.16 |
52-Week Low | $110.24 | $271.18 |
Enterprise Value | $38.59B | $243.95B |
Dividend Yield | 0.78% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Amgen (AMGN) trades at $368.10, down 1.62% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net income margin of 20.96% and has beaten earnings estimates for three consecutive quarters. Recent news includes a favorable court ruling blocking a price cap on Enbrel and analyst upgrades, though regulatory challenges for Tavneos in Europe pose headwinds. Cash flow from operations remains robust at nearly $10 billion annually.
The outlook for AMGN is positive with steady revenue growth and high margins, but investors face risks from patent expirations and regulatory scrutiny. Analyst consensus is bullish with a $358.25 price target, though the current price exceeds this, suggesting near-term consolidation may occur. The company's strong cash generation supports dividend payments, but high debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
